Molecular Basis of Glucagon-like Peptide 1 Docking to Its Intact Receptor Studied with Carboxyl-terminal Photolabile Probes*

The glucagon-like peptide 1 (GLP1) receptor is a member of Family B G protein-coupled receptors and represents an important drug target for type 2 diabetes. Despite recent solution of the structure of the amino-terminal domain of this receptor and that of several close family members, understanding of the molecular basis of natural ligand GLP1 binding to its intact receptor remains limited. The goal of this study was to explore spatial approximations between specific receptor residues within the carboxyl terminus of GLP1 and its receptor as normally docked. Therefore, we developed and characterized two high affinity, full-agonist photolabile GLP1 probes having sites for covalent attachment in positions 24 and 35. Both probes labeled the receptor specifically and saturably. Subsequent peptide mapping using chemical and proteinase cleavages of purified wild-type and mutant GLP1 receptor identified that the Arg131–Lys136 segment at the juxtamembrane region of the receptor amino terminus contained the site of labeling for the position 24 probe, and the specific receptor residue labeled by this probe was identified as Glu133 by radiochemical sequencing. Similarly, nearby residue Glu125 within the same region of the receptor amino-terminal domain was identified as the site of labeling by the position 35 probe. These data represent the first direct demonstration of spatial approximation between GLP1 and its intact receptor as docked, providing two important constraints for the modeling of this interaction. This should expand our understanding of the molecular basis of natural agonist ligand binding to the GLP1 receptor and may be relevant to other family members.

[1]  M. Wheeler,et al.  Characterization of glucagon-like peptide-1 receptor-binding determinants. , 2000, Journal of molecular endocrinology.

[2]  A. Couvineau,et al.  Peptide Agonist Docking in the N-terminal Ectodomain of a Class II G Protein-coupled Receptor, the VPAC1 Receptor , 2006, Journal of Biological Chemistry.

[3]  A. Couvineau,et al.  The N-Terminal Parts of VIP and Antagonist PG97–269 Physically Interact with Different Regions of the Human VPAC1 Receptor , 2008, Journal of Molecular Neuroscience.

[4]  D. Donnelly,et al.  A model for receptor–peptide binding at the glucagon‐like peptide‐1 (GLP‐1) receptor through the analysis of truncated ligands and receptors , 2003, British journal of pharmacology.

[5]  R. Riek,et al.  NMR structure and peptide hormone binding site of the first extracellular domain of a type B1 G protein-coupled receptor. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[6]  B. Göke,et al.  Five Out of Six Tryptophan Residues in the N-Terminal Extracellular Domain of the Rat GLP-1 Receptor Are Essential for its Ability to Bind GLP-1 , 1997, Peptides.

[7]  L. Miller,et al.  Importance of the Amino Terminus in Secretin Family G Protein-coupled Receptors , 2004, Journal of Biological Chemistry.

[8]  D. Donnelly,et al.  Peptide binding at the GLP-1 receptor. , 2007, Biochemical Society transactions.

[9]  K. Eckart,et al.  Structure/activity characterization of glucagon-like peptide-1. , 1994, European journal of biochemistry.

[10]  J. Vilardaga,et al.  The C-terminus ends of secretin and VIP interact with the N-terminal domains of their receptors , 1996, Peptides.

[11]  T. Lybrand,et al.  Spatial approximation between a photolabile residue in position 13 of secretin and the amino terminus of the secretin receptor. , 2003, Molecular pharmacology.

[12]  L. B. Knudsen,et al.  Structure-activity studies of glucagon-like peptide-1. , 1994, The Journal of biological chemistry.

[13]  H. Jüppner,et al.  Identification of Determinants of Inverse Agonism in a Constitutively Active Parathyroid Hormone/Parathyroid Hormone-related Peptide Receptor by Photoaffinity Cross-linking and Mutational Analysis* , 2001, The Journal of Biological Chemistry.

[14]  D. Gorenstein,et al.  Structure of glucagon-like peptide (7-36) amide in a dodecylphosphocholine micelle as determined by 2D NMR. , 1994, Biochemistry.

[15]  D. Donnelly,et al.  Met-204 and Tyr-205 are together important for binding GLP-1 receptor agonists but not their N-terminally truncated analogues. , 2004, Protein and peptide letters.

[16]  A. Couvineau,et al.  The vasoactive intestinal peptide (VIP) alpha-Helix up to C terminus interacts with the N-terminal ectodomain of the human VIP/Pituitary adenylate cyclase-activating peptide 1 receptor: photoaffinity, molecular modeling, and dynamics. , 2008, Molecular endocrinology.

[17]  Kjeld Madsen,et al.  Crystal Structure of the Ligand-bound Glucagon-like Peptide-1 Receptor Extracellular Domain* , 2008, Journal of Biological Chemistry.

[18]  H. Xu,et al.  Molecular recognition of parathyroid hormone by its G protein-coupled receptor , 2008, Proceedings of the National Academy of Sciences.

[19]  R. Stevens,et al.  High-Resolution Crystal Structure of an Engineered Human β2-Adrenergic G Protein–Coupled Receptor , 2007, Science.

[20]  L. Miller,et al.  Use of N,O-bis-Fmoc-D-Tyr-ONSu for introduction of an oxidative iodination site into cholecystokinin family peptides. , 2009, International journal of peptide and protein research.

[21]  T. Lybrand,et al.  Direct Identification of a Distinct Site of Interaction between the Carboxyl-terminal Residue of Cholecystokinin and the Type A Cholecystokinin Receptor Using Photoaffinity Labeling* , 1997, The Journal of Biological Chemistry.

[22]  Y. Cao,et al.  The amino-terminal fragment of the adenylate cyclase activating polypeptide (PACAP) receptor functions as a high affinity PACAP binding domain. , 1995, Biochemical and biophysical research communications.

[23]  T. Lybrand,et al.  Spatial Approximation between the Amino Terminus of a Peptide Agonist and the Top of the Sixth Transmembrane Segment of the Secretin Receptor* , 2004, Journal of Biological Chemistry.

[24]  Ruben Abagyan,et al.  ICM—A new method for protein modeling and design: Applications to docking and structure prediction from the distorted native conformation , 1994, J. Comput. Chem..

[25]  D Rodbard,et al.  Ligand: a versatile computerized approach for characterization of ligand-binding systems. , 1980, Analytical biochemistry.

[26]  R. Abagyan,et al.  Molecular Approximations between Residues 21 and 23 of Secretin and Its Receptor: Development of a Model for Peptide Docking with the Amino Terminus of the Secretin Receptor , 2007, Molecular Pharmacology.

[27]  L. Miller,et al.  Molecular Approximation between a Residue in the Amino-terminal Region of Calcitonin and the Third Extracellular Loop of the Class B G Protein-coupled Calcitonin Receptor* , 2004, Journal of Biological Chemistry.

[28]  L. Miller,et al.  Critical Contributions of Amino-terminal Extracellular Domains in Agonist Binding and Activation of Secretin and Vasoactive Intestinal Polypeptide Receptors. STUDIES OF CHIMERIC RECEPTORS (*) , 1995, The Journal of Biological Chemistry.

[29]  L. Miller,et al.  Insights into the structural basis of endogenous agonist activation of family B G protein-coupled receptors. , 2008, Molecular endocrinology.

[30]  J. W. Neidigh,et al.  Exendin-4 and glucagon-like-peptide-1: NMR structural comparisons in the solution and micelle-associated states. , 2001, Biochemistry.

[31]  L. Miller,et al.  Relationship Between Native and Recombinant Cholecystokinin Receptors: Role of Differential Glycosylation , 1996, Pancreas.

[32]  L. Miller,et al.  Demonstration of a Direct Interaction between Residue 22 in the Carboxyl-terminal Half of Secretin and the Amino-terminal Tail of the Secretin Receptor Using Photoaffinity Labeling* , 1999, The Journal of Biological Chemistry.

[33]  G. Bitan,et al.  Photoaffinity Cross-linking Identifies Differences in the Interactions of an Agonist and an Antagonist with the Parathyroid Hormone/Parathyroid Hormone-related Protein Receptor* , 2000, The Journal of Biological Chemistry.

[34]  R. Abagyan,et al.  Spatial Approximation between Secretin Residue Five and the Third Extracellular Loop of Its Receptor Provides New Insight into the Molecular Basis of Natural Agonist Binding , 2008, Molecular Pharmacology.

[35]  L. Suva,et al.  Parathyroid Hormone-Receptor Interactions Identified Directly by Photocross-linking and Molecular Modeling Studies* , 1998, The Journal of Biological Chemistry.

[36]  B. Gallwitz,et al.  GLP-1 GIP chimeric peptides define the structural requirements for specific ligand-receptor interaction of GLP-1 , 1996, Regulatory Peptides.

[37]  Oliver P. Ernst,et al.  Crystal structure of opsin in its G-protein-interacting conformation , 2008, Nature.

[38]  J. Livingston,et al.  Glucagon·Glucagon-like Peptide I Receptor Chimeras Reveal Domains That Determine Specificity of Glucagon Binding (*) , 1995, The Journal of Biological Chemistry.

[39]  H. Xu,et al.  Molecular Recognition of Corticotropin-releasing Factor by Its G-protein-coupled Receptor CRFR1* , 2008, Journal of Biological Chemistry.

[40]  D. Singleton,et al.  Structure-function analysis of a series of glucagon-like peptide-1 analogs. , 2009, The journal of peptide research : official journal of the American Peptide Society.

[41]  C. Strader,et al.  The amino terminal domain of the glucagon-like peptide-1 receptor is a critical determinant of subtype specificity. , 1996, Receptors & channels.

[42]  Renxiao Wang,et al.  Molecular modeling of the three-dimensional structure of GLP-1R and its interactions with several agonists , 2009, Journal of molecular modeling.

[43]  R. Stevens,et al.  The 2.6 Angstrom Crystal Structure of a Human A2A Adenosine Receptor Bound to an Antagonist , 2008, Science.

[44]  B. Wulff,et al.  Different domains of the glucagon and glucagon‐like peptide‐1 receptors provide the critical determinants of ligand selectivity , 2003, British journal of pharmacology.

[45]  P. Hajduk,et al.  Solution structure and mutational analysis of pituitary adenylate cyclase-activating polypeptide binding to the extracellular domain of PAC1-RS , 2007, Proceedings of the National Academy of Sciences.

[46]  N. Andersen,et al.  Medium-dependence of the secondary structure of exendin-4 and glucagon-like-peptide-1. , 2002, Bioorganic & medicinal chemistry.

[47]  H. Jüppner,et al.  Evidence for a Ligand Interaction Site at the Amino-Terminus of the Parathyroid Hormone (PTH)/PTH-related Protein Receptor from Cross-linking and Mutational Studies* , 1998, The Journal of Biological Chemistry.

[48]  H. Jüppner,et al.  Multiple Sites of Contact between the Carboxyl-terminal Binding Domain of PTHrP-(1–36) Analogs and the Amino-terminal Extracellular Domain of the PTH/PTHrP Receptor Identified by Photoaffinity Cross-linking* , 2001, Journal of Biological Chemistry.

[49]  L. Miller,et al.  Intrinsic photoaffinity labeling of native and recombinant rat pancreatic secretin receptors. , 1993, Gastroenterology.

[50]  R. Riek,et al.  Structure of the N-terminal domain of a type B1 G protein-coupled receptor in complex with a peptide ligand , 2007, Proceedings of the National Academy of Sciences.

[51]  R. Rudolph,et al.  Crystal structure of the incretin-bound extracellular domain of a G protein-coupled receptor , 2007, Proceedings of the National Academy of Sciences.